The AGA Center for Diagnostics and Therapeutics was pleased to host the AGA Biosimilars Roundtable on Dec. 3-4, 2017, in Washington, D.C. In attendance were 26 invited experts representing academic and private practice physicians from the U.S., Europe, and Canada, advanced practice providers, industry, FDA’s Center for Drug Evaluation and Research, Crohn’s and Colitis Foundation, and patent law. The roundtable’s objective was to identify key gaps in evidence and education related to biologics and biosimilars where AGA could take action on over the next few years.

The meeting proceedings have been submitted to Gastroenterology for review, and a white paper summarizing key recommendations from the meeting will follow later this year. Further, a session at DDW 2018 entitled “The Future of Biosimilars in Gastroenterology” is scheduled for Tuesday, June 4, 2018, and will feature talks from several roundtable participants. AGA will utilize the roundtable discussion and recommendations to inform the creation of an organization-wide education plan on biosimilars.